International Journal of Hematology

DOI: 10.1007/s12185-019-02707-w Pages: 1-5

Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

1. Hospital de la Santa Creu i Sant Pau, José Carreras Leukemia Research Institute and IIB Sant Pau, Universitat Autònoma de Barcelona, Hematology Department

2. Hospital de la Santa Creu i Sant Pau, Dermatology Department

Correspondence to:
Silvana Novelli
Tel: +34 93556 5649



Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge